Healthcare Professionals - Mississippi State Department of Health

Updated SARS-CoV-2 Reporting RequirementsMarch 31, 2022
Electronic Reporting of COVID-19 Test Results to MSDHOptions and data formats
Request NBS Account for COVID-19 ReportingChoose this option if you run non-rapid, non-point-of-care COVID-19 tests (typically hospitals, reference labs, large clinic systems, etc.)
Sign up for Simple Report for COVID-19 ReportingThis reporting tool only works with rapid and point-of-care COVID-19 tests (typically clinics, schools, and non-traditional testing sites). These facilities can view and edit data entered.

COVID-19 Deaths

Monoclonal Antibody Therapy

There are no monoclonal antibodies currently authorized in the U.S. for the outpatient treatment of COVID-19.

The following monoclonal antibody products are no longer authorized for use in the U.S.:

Bamlanivimab
Bamlanivimab/Etesevimab
Bebtelovimab
REGEN-COV
Sotrovimab

Evusheld

Ordering: The federal government has designed the Healthcare Provider Order Portal (HPOP) for management of COVID-19 therapeutics. Please place your order in HPOP. You will be able to see courses ordered for your site on your HPOP account. If you do not have an HPOP account, please contact C19Therapeutics@msdh.ms.gov

Required reporting: Courses administered and courses available of Evusheld should be entered into HPOP by the provider site at the end of every business day. Timely and accurate inventory reporting is necessary for federal partners to determine subsequent state allocations.

Resources:

Evusheld fact sheet for healthcare providers FDA
Evusheld fact sheet for patients/caregivers FDA
Video: COVID-19 Prevention for Special Populations and related links March 2022

Oral Antivirals

Required reporting: Courses administered and courses available of Paxlovid and molnupiravir should be entered into HPOP by the provider site at the end of every business day. Timely and accurate inventory reporting is necessary for federal partners to determine subsequent state allocations

Resources:

Find pharmacies that prescribe and dispense oral antivirals

Therapeutics Locator

Use this interactive map to locate a facility that has one of the authorized therapeutics for COVID-19.

View this locator full-screen

Presentation: Oral Antiviral Therapeutics

Overview and details of use, safety, interactions, target population and more (July 19, 2022)

Remdesivir

Remdesivir has been studied in non-hospitalized patients with mild to moderate COVID-19 who are at high risk of progressing to severe disease and is approved by the FDA for use in both hospitalized and non-hospitalized patients.

NIH Treatment Guidelines

Ordering: Remdesivir is commercially available and should be ordered through standard pharmaceutical procurement processes.

Billing for COVID-19 Therapeutics

CMS Billing

Health Facilities

Specimen Collection, Delivery and Reporting

Specimen Reporting

SARS-CoV-2 Virus Strain Surveillance

Map and Directions for Laboratory Dropoff

The Dr. F.E.”ED” Thompson, Jr. Public Health Laboratory Facility is on the State Department of Health's central office campus in Jackson, MS at 350 East Woodrow Wilson Drive, Jackson, 39216.

Local Delivery of Samples: Drop samples off at the rear of the Thompson lab building. Detailed instructions are in our sample shipping guidance.

Dropoff hours: Monday through Friday from 8:00–4:30.

Coronavirus COVID-19 Guidance and Information for Healthcare Professionals

Healthcare Guidance

MS-HAN Messages

Therapeutics

Healthcare Provider Guidance and Resources

Patient Handouts

Vaccination Providers

Reporting COVID-19 Cases